Holden SE - Search Results

1

Prevalence, glucose control and relative survival of people with Type 2 diabetes in the UK from 1991 to 2013.

Holden SE, Jenkins-Jones S, Morgan CL, Peters JR, Schernthaner G, Currie CJ. Holden SE, et al. Diabet Med. 2017 Jun;34(6):770-780. doi: 10.1111/dme.13332. Epub 2017 Mar 9. Diabet Med. 2017. PMID: 28173634

2

Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin.

Holden SE, Poole CD, Morgan CL, Currie CJ. Holden SE, et al. BMJ Open. 2011 Jan 1;1(2):e000258. doi: 10.1136/bmjopen-2011-000258. BMJ Open. 2011. PMID: 22021891 Free PMC article.

3

Endogenous hyperinsulinaemia and exogenous insulin: a common theme between atherosclerosis, increased cancer risk and other morbidities.

Holden SE, Currie CJ. Holden SE, et al. Atherosclerosis. 2012 May;222(1):26-8. doi: 10.1016/j.atherosclerosis.2012.01.052. Epub 2012 Feb 14. Atherosclerosis. 2012. PMID: 22387058 No abstract available.

4

The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010).

Holden SE, Jenkins-Jones S, Poole CD, Morgan CL, Coghill D, Currie CJ. Holden SE, et al. Child Adolesc Psychiatry Ment Health. 2013 Oct 11;7(1):34. doi: 10.1186/1753-2000-7-34. Child Adolesc Psychiatry Ment Health. 2013. PMID: 24119376 Free PMC article.

5

How many people inject insulin? UK estimates from 1991 to 2010.

Holden SE, Gale EA, Jenkins-Jones S, Currie CJ. Holden SE, et al. Diabetes Obes Metab. 2014 Jun;16(6):553-9. doi: 10.1111/dom.12260. Epub 2014 Feb 9. Diabetes Obes Metab. 2014. PMID: 24410846

6

Mortality risk with sulphonylureas compared to metformin.

Holden SE, Currie CJ. Holden SE, et al. Diabetes Obes Metab. 2014 Oct;16(10):885-90. doi: 10.1111/dom.12280. Epub 2014 Mar 14. Diabetes Obes Metab. 2014. PMID: 24533964

7

Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.

Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Morgan CL, et al. Among authors: holden se. Diabetes Obes Metab. 2014 Oct;16(10):957-62. doi: 10.1111/dom.12302. Epub 2014 May 8. Diabetes Obes Metab. 2014. PMID: 24720708

8

Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality.

Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Morgan CL, et al. Among authors: holden se. Diabetes Obes Metab. 2014 Oct;16(10):977-83. doi: 10.1111/dom.12306. Epub 2014 May 22. Diabetes Obes Metab. 2014. PMID: 24762119

9

Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment: (questionable) classification of diabetic patients based on combination of specific glucose-lowering drugs.

Holden SE, Bannister CA, Currie CJ. Holden SE, et al. Diabetologia. 2014 Sep;57(9):2001-2. doi: 10.1007/s00125-014-3281-1. Epub 2014 Jun 3. Diabetologia. 2014. PMID: 24891018 No abstract available.

10

Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin.

Currie CJ, Holden SE. Currie CJ, et al. Among authors: holden se. Diabetes Obes Metab. 2014 Oct;16(10):881-4. doi: 10.1111/dom.12349. Diabetes Obes Metab. 2014. PMID: 25040702 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters